Screen* Study Period 1 Study Period 2† Study day   0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 27 Inpatient confinement   x x x                         x x x x x x x x x                           Outpatient visit x       x x   x   x   x   x   x                   x x x x x x x x x x x x   Aripiprazole administration     x                                         x                             Aripiprazole PK blood sample     x x x x   x   x   x   x   x   x           x x x x   x   x   x   x   x   Desvenlafaxine administration                                   x x x x x x x x x x x x x x x x x x x     Desvenlafaxine  PK blood sample                                               x                             Adverse event monitoring x x ----------------------------------------------------------------------------x   x ---------------------------------------------------------------------------------------------------------------------x PK= Pharmacokinetics *Screening was conducted within 28 days before aripiprazole administration in study period 1 †Start of study period 2 was within 7 days of day 14 of study period

Table 1: Study design.

Goto home»